VSTM2B and breast carcinoma: Concurrent CN gains were observed not only for CCNE1 and URI but for six additional genes in close vicinity: C19Orf12, POP4, PLEKHF1, VSTM2B, UQCRFS1 and LOC284395. CCNE1 was once considered the exclusive oncogenic driver within the 19q12 amplicon [18], but the present study and recent studies on ovarian and breast carcinomas have identified co-amplified genes [6, 19] that may also contribute to tumour aggression or treatment resistance [6, 7].